A Review Article on Conversion of Pantoprazole Crystalline Form to Amorphous Form to Study the Effect of Solubility

Proton pump inhibitors (PPIs), like pantoprazole, are used to treat a number of ailments linked to high stomach acid. It is frequently recommended to treat acid reflux-induced erosive dysphagia, Zollinger-Ellison syndrome, and gastroesophageal reflux disease (GERD). It lessens the generation of acid by blocking the stomach lining's proton pump. One way to increase pantoprazole's bioavailability is to transform it from a crystalline to an amorphous form. Increased Solubility, Quicker Rates of Dissolution, Stability Enhancements Compared to crystalline forms, amorphous forms may be less thermodynamically stable, which could eventually cause recrystallization. To preserve the amorphous state and its advantages, proper formulation and storage conditions are crucial. One method that shows promise for increasing pantoprazole's solubility and bioavailability is converting it to its amorphous form.